Figure 3.

AngII reduces CT nerve responses to NaCl (amiloride-sensitive component) and enhances responses to sweeteners. A, Typical examples of CT nerve responses of B6 mice 30 min after intraperitoneal injection of 1000 ng/kg bw of AngII (lower traces) versus vehicle-injected controls (upper traces). B, CT nerve responses (normalized to 100 mm NH₄Cl) of B6 mice stimulated by indicated compounds 10–30 min after administration of vehicle (black bars) or 1000 ng/kg bw of AngII (red bars) (n = 7–17). Compounds tested: NaCl [300 mm NaCl]; Na + Ami [300 mm NaCl + 30 μm amiloride]; AS, the amiloride-sensitive NaCl component (obtained by subtracting Na + Ami from NaCl); Glc [500 mm glucose]; Suc [500 mm sucrose]; Sac [20 mm saccharin]; SC [1 mm SC45647]; KCl [100 mm KCl]; HCl [10 mm HCl]; MSG [100 mm monosodium glutamate + 30 Ami]; and QHCl [20 mm quinine HCl]. C, Concentration dependence of CT responses to NaCl, NaCl + Ami, and AS 10–30 min after administration of vehicle (black symbols) or 1000 ng/kg bw of AngII (red symbols) (n = 5–12). D, Concentration-dependent CT responses to sucrose 10–30 min after administration of vehicle (black symbols) or 1000 ng /kg bw of AngII (red symbols) (n = 12). E, Dose-dependent effect of AngII treatment on CT responses to 300 mm NaCl, 300 mm Na + 30 μm Ami, and 300 mm AS (n = 6–13; see Fig. 2 for details) (in each case the response magnitude to 300 mm NaCl, 300 mm Na + 30 μm Ami, or 300 mm AS after administration of vehicle control were normalized to be 100%). F, Dose-dependent effect of AngII treatment on CT nerve responses to 500 mm Suc and 100 mm KCl (n = 7–15) (in both cases the response magnitude to 500 mm Suc or 100 mm KCl after administration of vehicle control were normalized to be 100%). Asterisks indicate significant differences between AngII treatments and vehicle controls [*p < 0.05; **p < 0.01; ***p < 0.001; paired t test (B), post hoc t test following repeated two-way ANOVA (C–F)]. All data are presented as the mean ± SEM.